Expression pattern of circulating long non-coding RNA GAS5 as a novel biomarker in non-small cell lung cancer patients

Vesovic, Natasa; Tos̆ić, Nataša; Djurasevic, Teodora Karan; Andrić, Zoran; Zdravkovic, Darko; Pavlović, Sonja; Jovanović, Dragana

doi:10.5114/aoms.2020.98815

Cited by 3 publications

(8 citation statements)

References 23 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The primary applications for ddPCR are rare allele detection in heterogeneous samples like liquid biopsies or FFPE samples of solid tumors, non-invasive prenatal diagnostics, viral load detection, gene expression and copy number variation, single cell gene expression profiling, and the validation of low-frequency mutations identified by sequencing analysis. Moreover, epigenomic markers originating from tumor cells could be analyzed (methylation sites, circulating regulatory RNAs) [ 72 ]. A good agreement between BEAMing and ddPCR has been shown, with a kappa value of 0.91 (95% CI: 0.85–0.95) [ 73 ].…”

Section: Discussionmentioning

confidence: 99%

Meta-Analysis of Circulating Cell-Free DNA’s Role in the Prognosis of Pancreatic Cancer

Milin-Lazović

Madzarevic

Rajović

et al. 2021

Cancers

Self Cite

View full text Add to dashboard Cite

Introduction: The analysis of cell-free DNA (cfDNA) for genetic abnormalities is a promising new approach for the diagnosis and prognosis of pancreatic cancer patients. Insights into the molecular characteristics of pancreatic cancer may provide valuable information, leading to its earlier detection and the development of targeted therapies. Material and Methods: We conducted a systematic review and a meta-analysis of studies that reported cfDNA in pancreatic ductal adenocarcinoma (PDAC). The studies were considered eligible if they included patients with PDAC, if they had blood tests for cfDNA/ctDNA, and if they analyzed the prognostic value of cfDNA/ctDNA for patients’ survival. The studies published before 22 October 2020 were identified through the PubMED, EMBASE, Web of Science and Cochrane Library databases. The assessed outcomes were the overall (OS) and progression-free survival (PFS), expressed as the log hazard ratio (HR) and standard error (SE). The summary of the HR effect size was estimated by pooling the individual trial results using the Review Manager, version 5.3, Cochrane Collaboration. The heterogeneity was assessed using the Cochran Q test and I2 statistic. Results: In total, 48 studies were included in the qualitative review, while 44 were assessed in the quantitative synthesis, with the total number of patients included being 3524. Overall negative impacts of cfDNA and KRAS mutations on OS and PFS in PDAC (HR = 2.42, 95% CI: 1.95–2.99 and HR = 2.46, 95% CI: 2.01–3.00, respectively) were found. The subgroup analysis of the locally advanced and metastatic disease presented similar results (HR = 2.51, 95% CI: 1.90–3.31). In the studies assessing the pre-treatment presence of KRAS, there was a moderate to high degree of heterogeneity (I2 = 87% and I2 = 48%, for OS and PFS, respectively), which was remarkably decreased in the analysis of the studies measuring post-treatment KRAS (I2 = 24% and I2 = 0%, for OS and PFS, respectively). The patients who were KRAS positive before but KRAS negative after treatment had a better prognosis than the persistently KRAS-positive patients (HR = 5.30, 95% CI: 1.02–27.63). Conclusion: The assessment of KRAS mutation by liquid biopsy can be considered as an additional tool for the estimation of the disease course and outcome in PDAC patients.

show abstract

Section: Discussionmentioning

confidence: 99%

Meta-Analysis of Circulating Cell-Free DNA’s Role in the Prognosis of Pancreatic Cancer

Milin-Lazović

Madzarevic

Rajović

et al. 2021

Cancers

Self Cite

View full text Add to dashboard Cite

show abstract

“…Nowadays, more attention is directed to examine the impact of long noncoding RNAs (lncRNAs) on cancer pathology [8][9][10] . Long non-coding RNAs, often called "Genomic Dark Matter", are non-protein-coding transcripts with length of more than 200 nucleotides.…”

Section: Introductionmentioning

confidence: 99%

“…They can also interact with promoter or enhancer sequences to modulate gene expression and consequently, act as tumor suppressors or oncogenes [10][11][12][13] . The finding that lncRNAs originating from tumor cells can be detected in the plasma has prompted the idea to use lncRNAs as biomarkers in cancer patients 9 . Indeed, accumulated knowledge on lncRNAs have indicated their possible usage as diagnostic/prognostic markers and also as therapeutic targets in many tumors 14 .…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

The levels of circulating long non-coding RNA GAS5 in prostate cancer patients: Single center study

et al. 2022

View full text Add to dashboard Cite

Background/Aim. Prostate cancer (PCa) is second occurring carcinoma that affect males population. Although PCa incidence rates are high, most cases has favorable prognosis, with comfortable long term life quality. This study was aimed to assess distinction of lncRNA GAS5 plasma levels between healthy individuals and patients with PCa, and also between PCa patients with different prognostic scores. Methods. The present study included a total of 40 patients with PCa and a control group of 20 healthy individuals. PCa patients were divided into two subgroups (20 patients each) based on the prognostic criteria of American Joint Committee on Cancer. The patient data were collected and analysed. GAS5 levels were quantified using Real-time PCR metod. Statistical analysis was conducted using the IBM SPSS Statistics 26.0 computer program (IBM, USA, 2019). Results. The relative quantification of GAS5 expression levels shows downregulation in PCa patients compared to healthy individuals, however the difference was marginaly statistically significant (p = 0.056). With further analysis of the given results, we have concluded that the expression level of GAS5 was not significantly different in the first patient subgroup and the healthy individuals (p = 0.268). Patients from second subgroup had significantly lower plasma levels of GAS5 than healthy individuals (p = 0.033). Levels of GAS5 expression between patients with favorable prognosis (Group 1) than in the patients with worse prognostic score (Group 2), did not indicate the statistical significance (p = 0.275). In both Group 1 (p = 0.805) and Group 2 (p = 0.454), the plasma levels of GAS5 were not significantly different in comparing to the age (? 65 vs > 65 years). Conclusion. One of the main objective in PCa researching is identifying novel and more efficient biomarkers. Conducted research provides strong evidence about the significance of lncRNAs in PCa, as well as the correlation of decreased expression of GAS5 and poor prognosis in various tumours.

show abstract

“…In addition to studying the role of GAS5 in the pathogenesis of cancer, its potential role as a prognostic marker was also investigated. In numerous types of cancer, it has been shown that reduced GAS5 expression was associated with unfavorable clinical and pathological characteristics related to advanced stages of the disease, making it a marker for poor prognosis [ 11 , 12 , 13 ].…”

Section: Introductionmentioning

confidence: 99%

Expression Profiles of Long Non-Coding RNA GAS5 and MicroRNA-222 in Younger AML Patients

et al. 2021

Self Cite

View full text Add to dashboard Cite

Acute myeloid leukemia (AML) is a heterogeneous malignant disease both on clinical and genetic levels. AML has poor prognosis and, therefore, there is a constant need to find new prognostic markers, as well as markers that can be used as targets for innovative therapeutics. Recently, the search for new biomarkers has turned researchers’ attention towards non-coding RNAs, especially long non-coding RNAs (lncRNAs) and micro RNAs (miRNAs). We investigated the expression level of growth arrest-specific transcript 5 (GAS5) lncRNA in 94 younger AML patients, and also the expression level of miR-222 in a cohort of 39 AML patients with normal karyotype (AML-NK), in order to examine their prognostic potential. Our results showed that GAS5 expression level in AML patients was lower compared to healthy controls. Lower GAS5 expression on diagnosis was related to an adverse prognosis. In the AML-NK group patients had higher expression of miR-222 compared to healthy controls. A synergistic effect of GAS5low/miR-222high status on disease prognosis was not established. This is the first study focused on examining the GAS5 and miR-222 expression pattern in AML patients. Its initial findings indicate the need for further investigation of these two non-coding RNAs, their potential roles in leukemogenesis, and the prognosis of AML patients.

show abstract

Expression pattern of circulating long non-coding RNA GAS5 as a novel biomarker in non-small cell lung cancer patients

Cited by 3 publications

References 23 publications

Meta-Analysis of Circulating Cell-Free DNA’s Role in the Prognosis of Pancreatic Cancer

Meta-Analysis of Circulating Cell-Free DNA’s Role in the Prognosis of Pancreatic Cancer

The levels of circulating long non-coding RNA GAS5 in prostate cancer patients: Single center study

Expression Profiles of Long Non-Coding RNA GAS5 and MicroRNA-222 in Younger AML Patients

Contact Info

Product

Resources

About